Muhammad Alamgeer

903 total citations
25 papers, 615 citations indexed

About

Muhammad Alamgeer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Muhammad Alamgeer has authored 25 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Muhammad Alamgeer's work include Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Muhammad Alamgeer is often cited by papers focused on Lung Cancer Research Studies (9 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Muhammad Alamgeer collaborates with scholars based in Australia, United States and Singapore. Muhammad Alamgeer's co-authors include D. Neil Watkins, Vinod Ganju, Craig D. Peacock, Vishal Boolell, William Matsui, Beena Kumar, Zdenka Prodanovic, Michal Schneider, Caroline Lum and Daniel J. Gough and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Muhammad Alamgeer

25 papers receiving 606 citations

Peers

Countries citing papers authored by Muhammad Alamgeer

Since Specialization

Citations

This map shows the geographic impact of Muhammad Alamgeer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhammad Alamgeer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhammad Alamgeer more than expected).

Fields of papers citing papers by Muhammad Alamgeer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhammad Alamgeer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhammad Alamgeer. The network helps show where Muhammad Alamgeer may publish in the future.

Co-authorship network of co-authors of Muhammad Alamgeer

This figure shows the co-authorship network connecting the top 25 collaborators of Muhammad Alamgeer. A scholar is included among the top collaborators of Muhammad Alamgeer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muhammad Alamgeer. Muhammad Alamgeer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study 2024 ·The Medical Journal of Australia ·(unknown), Annette M. Lim, Mathias Bressel, Jenny Lee, Rahul Ladwa, Alexander Guminski, Brett Hughes, Samantha Bowyer, Karen Briscoe, S.J. Harris, (unknown), Robert Zielinski, Muhammad Alamgeer, Matteo S. Carlino, (unknown), John Park, Muhammad A. Khattak, Fiona Day, Danny Rischin	8
2	Oncology and intensive care doctors' perception of intensive care admission of cancer patients: A cross-sectional national survey 2024 ·Australian Critical Care ·(unknown), (unknown), Muhammad Alamgeer, Amanda Gwendolyn Stevanovic, Deme Karikios, Arvind Rajamani, Ashwin Subramaniam	2
3	FRailty in Australian patients admitted to Intensive care unit after eLective CANCER-related SURGery: a retrospective multicentre cohort study (FRAIL-CANCER-SURG study) 2024 ·British Journal of Anaesthesia ·Ryan Ruiyang Ling, Ryo Ueno, Muhammad Alamgeer, Krishnaswamy Sundararajan, Raghav Sundar, Michael Bailey, David Pilcher, Ashwin Subramaniam	5
4	Circulating Tumour DNA (ctDNA) as a Predictor of Clinical Outcome in Non-Small Cell Lung Cancer Undergoing Targeted Therapies: A Systematic Review and Meta-Analysis 2023 ·Cancers ·(unknown), Ashwin Subramaniam, Afroza Akhter, (unknown), Daniel J. Gough, Surein Arulananda, Muhammad Alamgeer	12
5	Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study 2023 ·Heart Lung and Circulation ·Sean Tan, (unknown), (unknown), (unknown), Adam J. Nelson, Muhammad Alamgeer, Nitesh Nerlekar, Eva Segelov, Stephen J. Nicholls	4
6	Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy 2023 ·JTO Clinical and Research Reports ·Yang Wang, (unknown), Muhammad Alamgeer, Sagun Parakh, Eldho Paul, Paul Mitchell, (unknown)	2
7	Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study 2023 ·The Lancet Healthy Longevity ·Muhammad Alamgeer, Ryan Ruiyang Ling, Ryo Ueno, Krishnaswamy Sundararajan, Raghav Sundar, David Pilcher, Ashwin Subramaniam	20
8	MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat 2023 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Daniel J. Garama, Muhammad Alamgeer, (unknown), Michael DeVeer, Vinod Ganju, D. Neil Watkins, Jason E. Cain, Daniel J. Gough	21
9	Treatment outcomes of standard (high dose) cisplatin and non‐standard chemotherapy for locally advanced head and neck cancer 2022 ·Cancer Reports ·Muhammad Alamgeer, A Coleman, Lachlan McDowell, Charles Giddings, Adnan Safdar, Elizabeth Sigston, Yang Wang, Ashwin Subramaniam	2
10	1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS] 2021 ·Annals of Oncology ·Andrew Haydon, Muhammad Alamgeer, Daniel Brungs, Frances A. Collichio, Nikhil I. Khushalani, (unknown), Danny Rischin, Ragini R. Kudchadkar, Wanxing Chai‐Ho, Gregory A. Daniels, Jose Lutzky, (unknown), Samantha Bowyer, Michael R. Migden, (unknown), Praveen K. Bommareddy, Shui He, Claudia Andreu‐Vieyra, (unknown), Andrew Hill	2
11	P01.22 Outcomes in NSCLC Patients with Early Termination of Immune Checkpoint Inhibitors Due to Toxicities 2021 ·Journal of Thoracic Oncology ·(unknown), (unknown), Muhammad Alamgeer	1
12	Preliminary study highlights the potential of immune checkpoint inhibitors in sarcomatoid mesothelioma 2020 ·Translational Lung Cancer Research ·Natasha K. Brockwell, Muhammad Alamgeer, Beena Kumar, Gareth Rivalland, Thomas John, Belinda S. Parker	16
13	Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer 2019 ·Cancers ·Caroline Lum, Muhammad Alamgeer	17
14	A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer 2017 ·Investigational New Drugs ·Muhammad Alamgeer, D. Neil Watkins, (unknown), Beena Kumar, Daniel J. Gough, Ben Markman, Vinod Ganju	35
15	P1.07-004 Updated Analysis of Phase II Study of HA-Irinotecan, a CD44-Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·Muhammad Alamgeer, Peter Briggs, Ben Markman, Peter Midolo, (unknown), Beena Kumar, Vinod Ganju	3
16	Impact of Pretreatment Combined 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Sweet Ping Ng, Steven David, Muhammad Alamgeer, Vinod Ganju	12
17	Genomic Characterisation of Small Cell Lung Cancer Patient-Derived Xenografts Generated from Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens 2014 ·PLoS ONE ·Tracy L. Leong, Kieren D. Marini, Fernando J. Rossello, (unknown), Prudence A. Russell, Zdenka Prodanovic, Beena Kumar, Vinod Ganju, Muhammad Alamgeer, Louis Irving, Daniel Steinfort, Craig D. Peacock, Jason E. Cain, Anette Szczepny, D. Neil Watkins	26
18	Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer 2014 ·Breast Cancer Research ·Muhammad Alamgeer, Vinod Ganju, Beena Kumar, Jane Fox, Stewart Hart, Michelle White, Marion Harris, John Stuckey, Zdenka Prodanovic, Michal Schneider, D. Neil Watkins	43
19	Novel therapeutic targets in non-small cell lung cancer 2013 ·Current Opinion in Pharmacology ·Muhammad Alamgeer, Vinod Ganju, D. Neil Watkins	67
20	The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer 2013 ·Thorax ·Muhammad Alamgeer, Vinod Ganju, Anette Szczepny, Prudence A. Russell, Zdenka Prodanovic, Beena Kumar, Zoe Wainer, Tracey J. Brown, Michal Schneider, Matthew Conron, Gavin Wright, D. Neil Watkins	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact